These NSCLC drugs are: doxorubicin hydrochloride (see Table 1); bevacizumab (see Table 2); erlotinib hydrochloride, everolimus, gemcitabine hydrochloride, paclitaxel albumin (see Table 3). This evidence concerns the gene ALB and non-small cell lung carcinoma.